The advent of novel systemic therapies has significantly enhanced survival outcomes in patients with metastatic breast cancer. In accordance with NCCN guidelines, treatment selection is increasingly informed by tumor biology, including hormone receptor status and HER2 expression. As such, precision medicine approaches are being leveraged to tailor therapy to individual patients, optimizing disease management and improving overall survival in this patient population as of 2020.